ArticleFrontiers in microbiology2019
Ceftazidime/avibactam Improves the Antibacterial Efficacy of Polymyxin B Against Polymyxin B Heteroresistant KPC-2-Producing
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Biofilm-Mediated Antimicrobial Resistance in PediatricAntibiotics (Basel, Switzerland) · 2026Review
- In vitro Screening for Synergistic Polymyxin B-Based Combinations Against KPC- Producing Carbapenem-ResistantDrug design, development and therapy · 2026Article
- An Investigation of Colistin Heteroresistance inBioMed research international · 2026Article
- Study on the heteroresistance of carbapenem-resistant Klebsiella pneumoniae to Tigecycline and Polymyxin B and antibacterial activity of combined drugs in vitro.BMC microbiology · 2025Article
- Heteroresistance is associated with mutations during low concentration of tigecycline therapy in multiple-resistant Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2025Article
- Overview of heteroresistance to multiple antibiotics in clinicalJAC-antimicrobial resistance · 2025Article
- Molecular characterization of carbapenem resistance mechanisms and phenotypic correlations in clinicalFrontiers in microbiology · 2025Article
- A novel small RNA PhaS contributes to polymyxin B-heteroresistance in carbapenem-resistantEmerging microbes & infections · 2024Article
- Detection and characterization of eravacycline heteroresistance in clinical bacterial isolates.Frontiers in microbiology · 2024Article
- Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Ceftazidime-Avibactam for the Treatment of Central Nervous System Infection Caused by Pan Drug-Resistant Carbapenem-Resistant Klebsiella Pneumoniae: A Case Report.Infection and drug resistance · 2024Article
- Article
- Causes of polymyxin treatment failure and new derivatives to fill the gap.The Journal of antibiotics · 2022Review
- Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaMolecules (Basel, Switzerland) · 2022Article
- Analysis of a Refractory Case of Pediatric Meningitis Caused byInfection and drug resistance · 2022Article
- Heteroresistance Is Associated WithFrontiers in microbiology · 2022Article
- Antibiotic Heteroresistance inInternational journal of molecular sciences · 2021Review
- Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae.Microbiology spectrum · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the increasing multidrug resistance and limited antibiotics, polymyxin B revived as the last resort for the treatment of carbapenemase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.